Introduction

Histone lysine methylation is a reversible process, dynamically regulated by both lysine methyltransferases and demethylases. In general, methylation of histone H3 lysine 4 (H3K4me), H3K36, or H3K79 is associated with active transcription, whereas methylation of H3K9, H3K27, or H4K20 is associated with gene silencing.

EZH2 is a highly conserved histone methyltransferase that specifically targets H3K27 and functions as a transcriptional repressor. Tissue microarray analysis of breast cancers identified consistent overexpression of EZH2, which was associated with tumor aggressiveness. The compound DZNep has been shown to inhibit EZH2, decrease methylation of H3K27 and selectively induce apoptosis of cancer cell lines, including MCF-7.

Histone lysine-specific demethylase 1 (LSD1) is the first identified histone lysine demethylase capable of specifically demethylating monomethylated and dimethylated lysine 4 of histone H3 (H3K4me1 and H3K4me2). LSD1 is highly expressed in ER-negative breast tumors, and hence LSD1 was suggested to serve as a predictive marker for aggressive breast tumor biology and a novel attractive therapeutic target for treatment of ER-negative breast cancers. LSD Inhibitor II has been shown to inhibit LSD1 and promote dimethylation of H3K4 and thus relieve gene silencing, as well as promoting toxicity of cancer cells.

Enhanced activity of histone-modifying enzymes such as LSD1 and EZH2 leads to epigenetic silencing of critical genes, such as tumor suppressor genes, that have been shown to play an important role in breast tumor tumorigenesis. A series of novel compounds that work as powerful inhibitors of histone methylation or demethylation are capable of inducing re-expression of aberrantly silenced genes important in breast tumorigenesis.
This application note demonstrates the ability to monitor the effect of histone methylase and demethylase inhibitors that selectively induce apoptosis in cancer cell lines. MCF-7 breast cancer cells stably expressing GFP, and human neonatal dermal fibroblasts stably expressing RFP, were incorporated to create a more in vivo-like cell model. Induction of apoptosis was monitored using fluorescent probes, while the photo proteins allowed differentiation of the final cytotoxic effect on the two cell types in the coculture. Mechanism of action studies of the inhibitors were then performed using antibodies to the specific histone H3 lysine residues and their methylated state. All assessments were made via digital microscopy using a cell imaging multimode reader.

Materials and methods

Materials

Cells

MCF-7 GFP cells (part number AKR-211) were purchased from Cell Biolabs, Inc. (San Diego, CA). MCF-7 cells (part number HTB-22) were purchased from ATCC (Manassas, VA). Human neonatal dermal fibroblasts (part number cAP-0008RFP) were purchased from Angio-Proteomie (Boston, MA). The MCF-7 cells were propagated in MEM α medium (part number 12561-049) plus fetal bovine serum, 10% (part number 10437-028), Pen-Strep, 1x (part number 15070-063), and human recombinant insulin (part number 12585-014) each from Life Technologies (Carlsbad, CA). The fibroblasts were propagated in Advanced DMEM medium (part number 12491-015) plus fetal bovine serum (FBS), 10% (part number 10437-028) and Pen-Strep-Glutamine, 1x (part number 10378-016), also from Life Technologies.

Experimental components

DZNep hydrochloride (part number SML0305) was purchased from Sigma-Aldrich (St. Louis, MO). Chaetocin (part number 382191) and LSD1 Inhibitor II (part number 489477) were purchased from EMD Millipore (Billerica, MA). Anti-H3K9me3 rabbit polyclonal (part number ab8898), anti-H3K27me3 mouse monoclonal (part number ab6002), anti-H3K4me2 goat polyclonal (part number ab11946), Alexa Fluor 555 labeled donkey anti-rabbit polyclonal (part number ab150074), and Alexa Fluor 594 labeled donkey anti-goat polyclonal (part number ab150132) were purchased from Abcam (Cambridge, MA). Alexa Fluor 488 labeled goat antimouse polyclonal (part number A-11017) was purchased from Life Technologies. Annexin V-iFluor 350 conjugate (part number 20070) and 7-aminoactinomycin D (part number 17501) were donated by AAT Bioquest (Sunnyvale, CA).

Agilent BioTek Cytation 5 cell imaging multimode reader

The Cytation 5 is a modular multimode microplate reader that combines automated digital microscopy and microplate detection. Cytation 5 cell imaging multimode reader includes filter- and monochromator-based microplate reading; the microscopy module provides up to 60x magnification in fluorescence, brightfield, color brightfield, and phase contrast. For live cell assays, Cytation 5 features temperature control to 65 °C, CO₂/O₂ gas control and dual injectors for kinetic assays. Shaking and Agilent BioTek Gen5 microplate reader and imager software are also standard. The instrument was used to image cells expressing fluorescent proteins, in addition to fluorescent probes and labeled 2° antibodies following compound incubation periods.

Agilent BioTek Gen5 microplate reader and imager software

Gen5 microplate reader and imager software controls the operation of the Cytation 5 for both automated digital microscopy and PMT-based microplate reading. Image acquisition is completely automated from sample translation, focusing, and exposure control. Cellular analysis allows for quantification of phenotypic and epigenetic effects following compound treatment.

Cytotoxicity probes

Annexin V-iFluor 350 conjugate: Annexins are a family of proteins that bind to phospholipid membranes in the presence of calcium. In apoptosis, phosphatidyserine (PS) is translocated to the outer leaflet of the plasma membrane. The appearance of PS on the cell surface is a universal indicator of the initial/intermediate stages of cell apoptosis and can be detected before morphological changes can be observed. Annexins are a valuable probe to detect apoptotic cells that have expressed PS on the cell surface. The 347 and 443 nm excitation and emission maxima of the 350 conjugate are compatible with the DAPI imaging filter cube of the Cytation 5.

7-aminoactinomycin D: 7-Amino actinomycin D (7-AAD) is a nonpermeant dye used to identify nonviable cells. Cells with damaged plasma membranes or with impaired/no cell metabolism are unable to prevent the dye from entering the cell. Once inside the cell, the dyes bind to intracellular DNA producing highly fluorescent adducts that identify the cells as nonviable. The 546 and 647 nm excitation and emission maxima of the probe are compatible with the Texas Red imaging filter cube of the Cytation 5.

Each probe allows multiplexing with cells expressing red and green fluorescent proteins.
Methods

Cell preparation and plating

Inhibitor cytotoxicity assessment: For cytotoxicity/cell number measurements, MCF-7 breast cancer cells expressing GFP and primary human dermal fibroblasts expressing RFP were added in a volume of 100 µL to eight columns of multiple 96-well black, clear-bottom collagen coated plates (Corning Life Sciences part number 356649) to create final concentrations of 1.0 × 10^4 cells/well for each cell type. The same procedure was incorporated for apoptosis/necrosis assessments, with the exception that MCF-7 GFP cells only were added to the plate.

Epigenetic mechanism of action determination: The same procedure as previously listed was incorporated, except for non-GFP expressing MCF-7 cells alone being used in the experiment.

Compound dosing

Following an overnight incubation at 37 °C/5% CO₂, medium was removed from all wells. Medium containing a titration of either DZNep (H3K27 methylation inhibitor), chaetocin (H3K9 methylation inhibitor), or lysine specific demethylase (LSD) Inhibitor II (increases H3K4 dimethylation) was then added to the first two columns of the plate. Medium alone was added to all remaining wells. This process was repeated daily, with inhibitor being added to two more columns each day to create incubation times of cells with inhibitor of 24, 48, 72, and 96 hours.

Agilent BioTek Cytation 5 image-based analysis

Inhibitor cytotoxicity assessment: Upon completion of the incubation period, compound containing medium was removed and replaced with either medium containing Hoechst 33342 for cytotoxicity/cell number measurements, or Annexin V-iFluor 350 conjugate and 7-AAD fluorescent probes for apoptosis/necrosis assessments. Imaging was then performed with the Cytation 5 using 4x or 20x objectives, followed by cellular analysis using Gen5 data analysis software.

Epigenetics mechanism of action determination: Compound and medium were once again removed following the 96-hour dosing period. Cells were then fixed, permeabilized, and incubated with 1° and 2° Ab, in addition to fluorescent probes specific for the epigenetic inhibitor being analyzed:

- DZNep – Histone H3K27me3 1° Ab; Alexa 488 2° Ab; Hoechst 33342; Texas Red phalloidin
- Chaetocin – Histone H3K9me3 1° Ab; Alexa 555 2° Ab; Hoechst 33342; Alexa 488 phalloidin
- LSD Inh. II – Histone H3K4me2 1° Ab; Alexa 594 2° Ab; Hoechst 33342; Alexa 488 phalloidin

Imaging was once again performed with the Agilent BioTek Cytation 5 using 4x and 20x objectives, followed by cellular analysis.

Results and discussion

Phenotypic cytotoxicity assessment

The ability to induce an eventual toxic effect in the target cell type by potential new anticancer therapies is critical. However, it is also important to incorporate an appropriate cell model. Tumors are made of multiple cell types, including cancer and stromal cells. Therefore, the inclusion of human dermal fibroblasts can create a more appropriate microenvironment for testing. The use of cells expressing fluorescent proteins has become increasingly popular for the identification of the effect that a molecule has on each specific cell type. DZNep, Chaetocin, and LSD Inh. II, all known to modify the state of histone lysine methylation, were tested to ascertain whether cytotoxicity was induced in cocultured cell types over the total dosing period.
3.3 μM DZNep:
24-hour treatment
3.3 μM DZNep:
48-hour treatment
3.3 μM DZNep:
72-hour treatment
3.3 μM DZNep:
96-hour treatment
1.1 μM Chaetocin:
24-hour treatment
1.1 μM Chaetocin:
48-hour treatment
1.1 μM Chaetocin:
72-hour treatment
1.1 μM Chaetocin:
96-hour treatment
1.1 μM LSD Inh. II:
24-hour treatment
1.1 μM LSD Inh. II:
48-hour treatment
1.1 μM LSD Inh. II:
72-hour treatment
1.1 μM LSD Inh. II:
96-hour treatment

B

DZNep 24 Hour % Cell Counts

DZNep 48 Hour % Cell Counts

DZNep 72 Hour % Cell Counts

DZNep 96 Hour % Cell Counts

% Untreated Well Cell Count

% Untreated Well Cell Count

% Untreated Well Cell Count

% Untreated Well Cell Count

[DZNep], nM

[DZNep], nM

[DZNep], nM

[DZNep], nM

Total Cells
MCF-7 Cells
Fibroblast Cells
Figure 1. Cytotoxic effect per cell type. (A) Fluorescent overlaid 20x images following 24-, 48-, 72-, and 96-hour incubations with DZNep, chaetocin, or LSD Inh. Il. Blue: Hoechst 33342 stained nuclei; green: GFP expressing MCF-7 cells; red: RFP expressing fibroblasts. Relative total and individual cell type counts calculated using captured 4x images from wells treated with (B) DZNep; (C) chaetocin; or (D) LSD Inh II. % untreated well cell count determined for each time point using the following formula: 
\[
\text{Cell Count}_{\text{Treated Well}} / \text{Cell Count}_{\text{Untreated Well}} \times 100.
\]
Fluorescence imaging illuminates cytotoxic effects on specific cell types using individual channels to capture the signal emitted by each fluorescent protein. DZNep reduces expression of GFP (Figure 1A), as well as selectively reduces MCF-7 cell numbers (Figure 1B), which agrees with previously published results. Chaetocin, while inhibiting H3K9 histone methyltransferase activity, is also a potent inducer of cellular ROS, which provides a broader effect on multiple cell types (Figures 1A and 1C). LSD Inh. II, known to inhibit the gene silencing effects of LSD1, highly expressed in ER-neg breast tumors, shows little effect on cell numbers (Figures 1A and 1D). This may indicate that while epigenetic modifications may be taking place, the downstream cytotoxic effects of the compound require an extended dosing period.
Determination of apoptotic and necrotic activity leading to cytotoxicity can also be performed with the addition of fluorescent probes (Figure 2). Chaetocin induces both apoptosis and necrosis within MCF-7 cells in a time and dose-dependent manner (Figures 2A and 2C). DZNep exerts a more controlled effect on the cells, activating apoptotic pathways, while exhibiting little to no necrotic activity over the dosing period (Figures 2A and 2B). LSD Inh. II shows no evidence of apoptotic or necrotic activity induction, confirming the results seen from the cytotoxicity assessment (Figure 2D).

Once conclusions have been made concerning the final phenotypic consequence of test molecule treatment, mechanism of action studies can be conducted to confirm the epigenetic modification incorporated to produce the downstream effect.

Figure 2. Apoptotic and necrotic activity determination. (A) Fluorescent overlaid 20x images following 24, 48, 72, and 96-hour incubations with DZNep or chaetocin. Blue: Annexin V-iFluor 350 apoptosis assay signal; red: 7-AAD necrosis assay signal; green: GFP expressing MCF-7 cells. Relative apoptotic and necrotic cell counts calculated using captured 4x images from wells treated with (B) DZNep; (C) chaetocin; or (D) LSD Inhl II, using formula explained in Figure 1.

Epigenetic mechanism of action determination

The combination of phenotypic analysis with mechanism of action determinations is increasingly adapted within the drug discovery arena, and provides a complete picture of the effects of test molecules, including epigenetic inhibitors. The incorporation of primary antibodies specific for methylation states of particular histone lysine amino acids, coupled with fluorescently labeled secondary antibodies, present a sensitive and specific method to detect potential epigenetic modifications. The fact that these modifications take place within the nucleus of the target cell also allows the incorporation of a nuclear dye, and subpopulation analysis to be performed by Gen5 data analysis software.
DZNep inhibits the activity of EZH2, and decreases methylation of H3K27. Because the primary antibody added to these wells binds to trimethylated H3K27, as compound incubation times increase, the level of fluorescence emitted from the fluorescently labeled secondary antibody decreases in a dose-dependent manner (Figures 3A and 3D). Chaetocin inhibits methylation of H3K9. Therefore, a similar phenomenon is seen with this molecule. However, as seen previously, chaetocin also has a more potent cytotoxic effect on MCF-7 cells, causing a dramatic loss in cell number soon after the epigenetic effect is seen (Figures 3B and 3E). Finally, LSD Inhibitor II diminishes the demethylating activity of LSD1, allowing increased methylation of H3K4. An increase in binding of the H3K4me2 primary antibody is then the consequence of increasing compound incubation (Figures 3C and 3F), which could then lead to the toxic phenotypic effects previously seen in the literature.

The results shown above validate the mechanisms of action exhibited by the test compounds, and also confirms the ability of the Cytation 5 to detect modifications in the epigenetic state of treated and untreated cancer cell models.

**Conclusion**

The incorporation of cell lines expressing fluorescent proteins (FP) allows for simplified, rapid detection of the cytotoxic effect of cocultured cell models through the widefield microscopy capability of the Agilent BioTek Cytation 5 cell imaging multimode reader. Live cell assays can also be multiplexed with FP expressing cells to further understand the phenotypic effects of test molecules, using the multiple, individual imaging channels of the Cytation 5. Cellular analysis to determine live, apoptotic, and necrotic cell numbers following prescribed incubation periods is accurately carried out in an automatic fashion using Agilent BioTek Gen5 microplate reader and imager software. Assessment of modifications to the methylation state of target histone lysine residues are also possible using antibody-based detection, and the subpopulation capabilities of the Gen5 software. The combination of cell model, sensitive live or fixed cell detection, and image-based cellular analysis provides an ideal approach to better understand the phenotypic effects and epigenetic mechanisms of action of potential new anticancer therapies.
References


